Journal: JTO Clinical and Research Reports

Article Title: Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

doi: 10.1016/j.jtocrr.2020.100093

Figure Lengend Snippet: Baseline and progression biopsies analyzed for PD-L1 and CD3 modulation of PD-L1 expression and CD3 pos lymphocytes in two patients at progression (×200 magnification; epithelioid and biphasic). PD-L1 increased from 10% to 30% (in epithelioid disease) and 0% to 5% (in biphasic disease) with clustering of CD3 pos T cells in both patients at progression. PD-L1, programmed death-ligand 1; pos, positive.

Article Snippet: The expression of programmed death-ligand 1 (PD-L1) (Cell Signaling Technology E1L3N and Ventana-Roche SP-263 antibodies) and CD3 (Ventana-Roche 2GV6 antibody) was performed subsequent to the CD68 staining using residual tissue.

Techniques: Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: Ginsenoside Rb1 protects cardiomyocytes from oxygen-glucose deprivation injuries by targeting microRNA-21

doi: 10.3892/etm.2019.7330

Figure Lengend Snippet: GS-Rb1 decreases PDCD4 in NRCMs damaged by OGD. NRCMs were untreated, treated with a miR-21 inhibitor, treated with GS-Rb1 under OGD for 18 h or co-treated with 32 µM GS-Rb1 and a miR-21 inhibitor under OGD for 18 h. (A) Western blot analysis and (B) quantification of western blot analysis for PDCD4. Data is represented as the mean ± standard deviation. ***P<0.001 vs. the control group; ++P<0.01 and +++P<0.001 vs. the OGD group (n=3). GS-Rb1, ginsenoside Rb1; NRCMs, neonatal rat cardiomyocytes; OGD, oxygen-glucose deprivation; miR, microRNA; PDCD4, programmed cell death protein 4.

Article Snippet: The following primary antibodies were utilized: B-cell lymphoma (Bcl-2; 1:1,000; cat. no. 2872), Bcl-2-associated X protein (Bax; 1:1,000; cat. no. 2772), cytochrome c (1:1,000; cat. no. 4272), PDCD4 (1:1,000; cat. no. 9535) and GAPDH (1:1,000; cat. no. 2118; all, Cell Signaling Technology, Inc., Danvers, MA, USA).

Techniques: Western Blot, Standard Deviation